Revisiting Richter transformation in the era of novel CLL agents
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F21%3AN0000029" target="_blank" >RIV/00098892:_____/21:N0000029 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/21:73606360
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0268960X21000308" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0268960X21000308</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.blre.2021.100824" target="_blank" >10.1016/j.blre.2021.100824</a>
Alternative languages
Result language
angličtina
Original language name
Revisiting Richter transformation in the era of novel CLL agents
Original language description
Richter transformation (RT) is the development of aggressive lymphoma – most frequently diffuse large B-cell lymphoma (DLBCL) and rarely Hodgkin lymphoma (HL) – arising on the background of chronic lymphocytic leukaemia (CLL). Despite recent advances in CLL treatment, RT also develops in patients on novel agents, usually occurring as an early event. RT incidence is lower in CLL patients treated with novel agents in the front line compared to relapsed/refractory cases, with a higher incidence in patients with TP53 disruption. The genetic heterogeneity and complexity are higher in RT-DLBCL than CLL; the genetics of RT-HL are largely unknown. In addition to TP53, aberrations in CDKN2A, MYC, and NOTCH1 are common in RT-DLBCL; however, no distinct RT-specific genetic aberration is recognised yet. RT-DLBCL on ibrutinib is frequently associated with BTK and PLCG2 mutations. Here, we update on genetic analysis, diagnostics and treatment options in RT in the era of novel agents.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Reviews
ISSN
0268-960X
e-ISSN
1532-1681
Volume of the periodical
49
Issue of the periodical within the volume
September
Country of publishing house
GB - UNITED KINGDOM
Number of pages
19
Pages from-to
100824
UT code for WoS article
000686765400001
EID of the result in the Scopus database
2-s2.0-85103291631